ストックスクリーナーアプリを入手
23.75
1.29%
-0.31
アフターアワーズ：
23.75
Pacira Biosciences Inc (PCRX) 最新ニュース
Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus
Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures - marketscreener.com
Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus
Hip replacement patients with back pain used fewer opioids with EXPAREL - Stock Titan
(PCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Investment Recap: Can Pacira BioSciences Inc expand its profit marginsWeekly Trade Report & Risk Controlled Daily Plans - baoquankhu1.vn
PCRX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Weekly Earnings: Is Pacira BioSciences Inc stock a falling knife or bargain buy2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
PCRX Should I Buy - Intellectia AI
PCRX.O PE Ratio & Valuation, Is PCRX.O Overvalued - Intellectia AI
PCRX News & Events - Intellectia AI
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Pacira investors get live access to Needham healthcare event April 15 - Stock Titan
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
PCRX Technical Analysis & Stock Price Forecast - Intellectia AI
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK
Analysts Set Expectations for PCRX Q1 Earnings - MarketBeat
(PCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
2026-03-31 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence - Insider Monkey
Hennion & Walsh Asset Management Inc. Acquires 87,210 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Bitget
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Ortho Spine News
Study data linked EXPAREL to lower knee and spine surgery costs - Stock Titan
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Bull Run: Is Pacira BioSciences Inc impacted by rising ratesQuarterly Profit Report & Expert Curated Trade Ideas - baoquankhu1.vn
Vanguard amends Schedule 13G/A after internal realignment (PCRX) - stocktitan.net
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays - MarketBeat
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh - GuruFocus
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - gurufocus.com
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com South Africa
Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Australia
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):